Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

New Delhi: The drug major Sanofi Healthcare has got approval from the Subject Expert Committee (SEC) functional under the ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

In September, the use of a Sanofi immuno-inflammatory medicine to treat chronic obstructive pulmonary disease (COPD) was ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Kymera Therapeutics is pivoting focus from oncology to immunology, with plans to only develop cancer programs beyond phase 1 studies via partnerships. | Kymera Therapeutics is pivoting its focus from ...

Global medical companies are launching hundreds of state-of-the-art technologies in the medical product pavilion of the ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi will keep a significant stake in the company ... Dupixent is now approved for COPD in more than 30 countries, including the US and China, where COPD is a huge unmet medical need due to ...